Young lady sitting on the stairs smiling

CSL Limited, CSL Behring's parent company, has released the 2018/19 Annual Report

Portrait Photo of CSL Graduates

Learn More about CSL's Graduate Program.

Two research scientist in a lab

Our R&D Capabilities and Therapeutic Area focus, enables us to deliver on our promise to patients.

CSL Logo

CSL Donates to Indonesian Relief Operations

CSL, the parent company of CSL Behring, today announced an AUD$50,000 donation in sup…

09 Oct 2018 Company
Image of Thomson Reuters Top 100 Company 2018 logo for Diversity & Inclusion Index

CSL a Top 100 Company for Diversity & Inclusion

Thomson Reuters Includes the Global Biotechnology Leader in its 2018 Top 100 Global D…

18 Sep 2018 Company
red text logo for CSL Behring

First SCIg Approved for CIDP

HIZENTRA, the First Subcutaneous Immunoglobulin (SCIg) Approved for CIDP

17 Sep 2018 Company
World Haemophilia Day

World Haemophilia Day

CSL Behring Marks World Haemophilia Day by Shipping Bleeding Disorders Medicines to t…

17 Apr 2018 Company
Broadmeadows research scientist

Patient Enrolled in CSL112 Clinical Trial

The AEGIS-II trial will enrol more than 17,000 patients from approximately 1,000 medi…

23 Mar 2018 Company
Forbes Global World's Best Employers Logo

Making Forbes’ Top Global Employers List

Global biotech leader rated at no. 42 for patient focus, innovation and sustainable g…

20 Mar 2018 Company

Join us and make history with the brightest, most passionate people from every discipline.

Learn More

Innovation spans across our organization with a focus on solving patients' unmet needs.

Learn More
Latest News

Find out what's happening now at CSL Behring.

Learn More